NZ545835A - Dimethoxy docetaxel acetone solvate and method for the preparation thereof - Google Patents
Dimethoxy docetaxel acetone solvate and method for the preparation thereofInfo
- Publication number
- NZ545835A NZ545835A NZ545835A NZ54583504A NZ545835A NZ 545835 A NZ545835 A NZ 545835A NZ 545835 A NZ545835 A NZ 545835A NZ 54583504 A NZ54583504 A NZ 54583504A NZ 545835 A NZ545835 A NZ 545835A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hydroxy
- acetone
- oxotax
- benzoyloxy
- acetoxy
- Prior art date
Links
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000012453 solvate Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title description 2
- 229960003668 docetaxel Drugs 0.000 title description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 17
- ZVAFCKLQJCZGAP-WDEREUQCSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-WDEREUQCSA-N 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000010899 nucleation Methods 0.000 claims abstract description 7
- 239000000725 suspension Substances 0.000 claims abstract description 6
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- MSVWUXLRSKRKFZ-IPMKNSEASA-N (2r,4s,5r)-2-(4-methoxyphenyl)-3-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenyl-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1[C@@H]1N(C(=O)OC(C)(C)C)[C@@H](C=2C=CC=CC=2)[C@H](C(O)=O)O1 MSVWUXLRSKRKFZ-IPMKNSEASA-N 0.000 claims 1
- OZUCDJFMALKZOS-UHFFFAOYSA-N 2-(butoxycarbonylamino)-2-hydroxy-3-phenylpropanoic acid Chemical compound CCCCOC(=O)NC(O)(C(O)=O)CC1=CC=CC=C1 OZUCDJFMALKZOS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005855 radiation Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZHXYSICWKISVCX-VZXYPILPSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid;propan-2-one Chemical compound CC(C)=O.CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZHXYSICWKISVCX-VZXYPILPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0311016A FR2859996B1 (fr) | 2003-09-19 | 2003-09-19 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| PCT/FR2004/002344 WO2005028462A1 (fr) | 2003-09-19 | 2004-09-16 | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ545835A true NZ545835A (en) | 2009-10-30 |
Family
ID=34224354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ545835A NZ545835A (en) | 2003-09-19 | 2004-09-16 | Dimethoxy docetaxel acetone solvate and method for the preparation thereof |
Country Status (37)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160653A1 (en) * | 2006-03-21 | 2010-06-24 | Dr. Reddy's Laboratories Ltd. | Docetaxel polymorphs and processes |
| US7855591B2 (en) * | 2006-06-07 | 2010-12-21 | Atmel Corporation | Method and system for providing a charge pump very low voltage applications |
| US7652522B2 (en) * | 2006-09-05 | 2010-01-26 | Atmel Corporation | High efficiency low cost bi-directional charge pump circuit for very low voltage applications |
| JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス， インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| AU2013205442B2 (en) * | 2008-01-17 | 2016-05-12 | Aventis Pharma S.A. | Crystalline forms of dimethoxy docetaxel and methods for preparing same |
| WO2010019233A1 (en) | 2008-08-11 | 2010-02-18 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| FR2945211A1 (fr) * | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
| EP2493466B1 (en) * | 2009-10-29 | 2021-03-10 | Sanofi Mature IP | Novel antitumoral use of cabazitaxel |
| CA2708489A1 (en) * | 2009-10-29 | 2011-04-29 | Aventis Pharma S.A. | Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer |
| AU2015200149B2 (en) * | 2009-10-29 | 2016-12-01 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| WO2012142117A1 (en) | 2011-04-12 | 2012-10-18 | Plus Chemicals Sa | Solid state forms of cabazitaxel and processes for preparation thereof |
| WO2013024495A1 (en) * | 2011-08-18 | 2013-02-21 | Dr. Reddys Laboratories Limited | Pharmaceutical formulations of cabazitaxel |
| TWI526437B (zh) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
| CN103906747A (zh) | 2011-10-31 | 2014-07-02 | 台湾神隆股份有限公司 | 卡巴他赛及其中间体的制备方法 |
| DE112012004569T5 (de) | 2011-11-01 | 2014-08-14 | Fresenius Kabi Oncology Ltd. | Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon |
| EP2785701B1 (en) | 2011-11-28 | 2019-01-02 | Fresenius Kabi Oncology Limited | Crystalline form of carbazitaxel and process for preparation thereof |
| WO2013088335A1 (en) | 2011-12-13 | 2013-06-20 | Aventis Pharma S.A. | Crystalline form of cabazitaxel and process for preparing the same |
| WO2013111157A1 (en) * | 2012-01-03 | 2013-08-01 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
| AU2013217964A1 (en) * | 2012-02-10 | 2014-08-28 | Aventis Pharma S.A. | New pediatric uses of cabazitaxel |
| US9394266B2 (en) | 2012-03-08 | 2016-07-19 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102675257B (zh) * | 2012-05-10 | 2014-07-02 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
| CN102746258B (zh) | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| US9012665B2 (en) | 2012-07-31 | 2015-04-21 | Yung Shin Pharm. Ind. Co., Ltd. | Amorphous cabazitaxel |
| US9198969B2 (en) | 2012-08-15 | 2015-12-01 | Yung Shin Pharm. Ind. Co., Ltd. | Stable pharmaceutical formulation of cabazitaxel |
| CN103664836B (zh) * | 2012-09-20 | 2016-04-20 | 齐鲁制药有限公司 | 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法 |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CN103804323A (zh) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | 一种卡巴他赛溶剂化物及其制备方法和应用 |
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
| EP2743264A1 (en) | 2012-12-13 | 2014-06-18 | INDENA S.p.A. | New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
| CN103910698B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛丙酮合物及其结晶 |
| CN103910696B (zh) * | 2012-12-30 | 2016-01-20 | 上海医药工业研究院 | 卡巴他赛异丙醚合物及其结晶 |
| EP2777691A1 (en) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| WO2015000165A1 (zh) * | 2013-07-04 | 2015-01-08 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
| CN104277014A (zh) * | 2013-07-04 | 2015-01-14 | 北京新天宇科技开发有限公司 | 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法 |
| EP2865674A1 (en) | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Crystalline solvate forms of Cabazitaxel |
| EP2865675A1 (en) * | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
| CN103601704B (zh) * | 2013-11-22 | 2015-05-06 | 石家庄智恒医药科技有限公司 | 无定形卡巴他赛的制备 |
| ES2904505T3 (es) | 2015-01-12 | 2022-04-05 | Emcure Pharmaceuticals Ltd | Formulación líquida de cabazitaxel |
| EP3258931B1 (en) | 2015-02-17 | 2020-08-12 | Erasmus University Medical Center Rotterdam | Use of cabazitaxel in the treatment of prostate cancer |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| US10188626B2 (en) | 2015-11-03 | 2019-01-29 | Cipla Limited | Stabilized cabazitaxel formulations |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| EP3675863A4 (en) | 2017-09-01 | 2021-01-27 | PTC Therapeutics MP, Inc. | PHARMACEUTICAL COMPOSITION CONSISTING OF SEPIAPTERIN AND ITS USES |
| MX2020012980A (es) | 2018-05-30 | 2021-04-29 | Ptc Therapeutics Mp Inc | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. |
| MX2020012979A (es) | 2018-05-30 | 2021-04-29 | Ptc Therapeutics Mp Inc | Métodos para aumentar la exposición al plasma de sepiapterina. |
| WO2020249507A1 (en) | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it |
| EP3797834A1 (en) | 2019-09-25 | 2021-03-31 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
| EP3808345A1 (en) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| FR2722191B1 (fr) * | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle |
| DE4425978C1 (de) * | 1994-07-22 | 1995-11-23 | Karlsruhe Forschzent | Verfahren zur Herstellung keramischer Mikrostrukturen |
| MA23823A1 (fr) * | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| FR2745814B1 (fr) * | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
| US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| EP0982027A1 (en) * | 1998-08-17 | 2000-03-01 | Aventis Pharma S.A. | Taxoid derivatives for treating abnormal cell proliferation of the brain |
| US6136989A (en) * | 1998-12-30 | 2000-10-24 | Phytogen Life Sciences, Incorporated | Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material |
| US5969165A (en) * | 1999-01-07 | 1999-10-19 | 508037 (Nb) Inc. | Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column |
| JP2002544269A (ja) * | 1999-05-17 | 2002-12-24 | ブリストル−マイヤーズ スクイブ カンパニー | パクリタキセルおよびパクリタキセル類似体の製造におけるシリルエーテルの切断のための新規反応条件 |
| PT1457492E (pt) * | 2001-11-29 | 2008-02-28 | Daiichi Sankyo Co Ltd | Cristais de um derivado de taxano e processo para a sua produção |
-
2003
- 2003-09-19 FR FR0311016A patent/FR2859996B1/fr not_active Expired - Lifetime
-
2004
- 2004-08-19 PE PE2004000799A patent/PE20050870A1/es not_active Application Discontinuation
- 2004-09-16 RU RU2006113122/04A patent/RU2342373C2/ru active Protection Beyond IP Right Term
- 2004-09-16 AR ARP040103329A patent/AR045667A1/es not_active Application Discontinuation
- 2004-09-16 ME MEP-2008-117A patent/ME00054B/me unknown
- 2004-09-16 MX MXPA06002639A patent/MXPA06002639A/es active IP Right Grant
- 2004-09-16 EP EP04787385A patent/EP1667986B1/fr not_active Expired - Lifetime
- 2004-09-16 SI SI200432016T patent/SI1667986T1/sl unknown
- 2004-09-16 BR BRPI0414492A patent/BRPI0414492A8/pt not_active Application Discontinuation
- 2004-09-16 UA UAA200604360A patent/UA87115C2/ru unknown
- 2004-09-16 CA CA002539309A patent/CA2539309A1/fr not_active Abandoned
- 2004-09-16 AU AU2004274212A patent/AU2004274212B2/en active Active
- 2004-09-16 ME MEP-117/08A patent/MEP11708A/xx unknown
- 2004-09-16 ES ES04787385T patent/ES2403149T4/es not_active Expired - Lifetime
- 2004-09-16 WO PCT/FR2004/002344 patent/WO2005028462A1/fr active Application Filing
- 2004-09-16 RS YUP-2006/0189A patent/RS20060189A/sr unknown
- 2004-09-16 PL PL04787385T patent/PL1667986T3/pl unknown
- 2004-09-16 CN CNB200480026128XA patent/CN100429207C/zh not_active Expired - Lifetime
- 2004-09-16 DK DK04787385.6T patent/DK1667986T3/da active
- 2004-09-16 PA PA20048612401A patent/PA8612401A1/es unknown
- 2004-09-16 KR KR1020067005396A patent/KR101123588B1/ko not_active Expired - Lifetime
- 2004-09-16 JP JP2006526663A patent/JP5010279B2/ja not_active Expired - Lifetime
- 2004-09-16 PT PT4787385T patent/PT1667986E/pt unknown
- 2004-09-16 NZ NZ545835A patent/NZ545835A/en not_active IP Right Cessation
- 2004-09-16 RS RS20060189A patent/RS54614B1/en unknown
- 2004-09-16 HR HRP20130322TT patent/HRP20130322T1/hr unknown
- 2004-09-17 TW TW093128097A patent/TWI382022B/zh not_active IP Right Cessation
- 2004-09-17 MY MYPI20043787A patent/MY136668A/en unknown
- 2004-09-17 US US10/944,254 patent/US7241907B2/en active Active
-
2006
- 2006-03-09 IL IL174240A patent/IL174240A/en active IP Right Grant
- 2006-03-15 CR CR8292A patent/CR8292A/es unknown
- 2006-03-17 ZA ZA200602255A patent/ZA200602255B/en unknown
- 2006-03-17 MA MA28881A patent/MA28045A1/fr unknown
- 2006-03-17 TN TNP2006000086A patent/TNSN06086A1/en unknown
- 2006-04-19 NO NO20061714A patent/NO335997B1/no active Protection Beyond IP Right Term
-
2013
- 2013-03-20 LU LU92172C patent/LU92172I2/fr unknown
- 2013-04-16 CY CY20131100313T patent/CY1114575T1/el unknown
- 2013-05-13 CY CY2013016C patent/CY2013016I1/el unknown
- 2013-06-07 HU HUS1300025C patent/HUS1300025I1/hu unknown
- 2013-06-13 BE BE2013C036C patent/BE2013C036I2/fr unknown
- 2013-07-04 FR FR13C0037C patent/FR13C0037I2/fr active Active
-
2015
- 2015-04-22 NO NO2015013C patent/NO2015013I1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ545835A (en) | Dimethoxy docetaxel acetone solvate and method for the preparation thereof | |
| RU2341530C2 (ru) | Термостойкий кристаллический гидрохлорид эпирубицина и способ его получения | |
| RU2106353C1 (ru) | Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2 | |
| WO2010039159A1 (en) | Thermally stable crystalline epirubicin hydrochloride | |
| SK281958B6 (sk) | Trihydrát (2r,3s)-4,10-diacetoxy-2alfa-benzoyloxy-5beta,20- epoxy-1,7beta-dihydroxy-9-oxo-tax-11-en-13alfa-yl-3- benzoylamino-2-hydroxy-3-fenylpropionátu a spôsob jeho výroby | |
| RU2132841C1 (ru) | Способ очистки окситетрациклина и промежуточный продукт | |
| AU2020229932B2 (en) | Salt of aldose reductase inhibitor, and preparation method and application thereof | |
| JP2005314360A (ja) | ５−アミノレブリン酸スルホン酸塩及びその製造方法 | |
| RU2176505C2 (ru) | Средство, обладающее противовирусной активностью, на основе соединений серебра и золота с тиазином и способ его получения | |
| Botta et al. | 6-Alkyl-2-hethoxy-4-(3h)-pyrimidinones in the transformation of pyrimidines: regiospecific preparation, antitumor and antimicrobial activity of 4-O-acylated pyrimidine derivatives. New agents for selective acylation of amines | |
| SI20817A (sl) | Postopki za kristalizacijo N-(1(S)-etoksikarbonil-3-fenilpropil)-L-alanin N-karboksianhidrida | |
| HK1093340B (en) | Dimethoxy docetaxel acetone solvate et method for the preparation thereof | |
| SU1299510A3 (ru) | Способ получени производных хиназолинона | |
| US4978783A (en) | 2,6-dimethoxyhydroquinone-3-mercaptopropionic acid, 2,6-dimethoxyhydroquinone-3-mercaptoacetic acid, and antitumor use thereof | |
| DE69711112T2 (de) | Sulfonat von Glutathion-Monoester | |
| CN109970827A (zh) | 加米霉素中间体化合物i的晶型及其制备方法和应用 | |
| EP0045415A1 (en) | Di-L-cysteine L-malate and process for the production thereof | |
| Moiseeva | SYNTHESIS AND BIOLOGICAL ACTIVITY OF THE DAUNORUBICIN DERIVATIVES BEARING A BENZO [d][1, 3] DIOXOL-5-YL MOIETY | |
| PL52448B1 (enEXAMPLES) | ||
| HK1150603A1 (en) | Crystalline forms of dimethoxy docetaxel and methods for preparing same | |
| JP2001064229A (ja) | ケトール化合物の保存方法 | |
| JPH03188095A (ja) | ポリエン系抗生物質の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2017 BY CPA GLOBAL Effective date: 20140731 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2018 BY CPA GLOBAL Effective date: 20170803 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2019 BY CPA GLOBAL Effective date: 20180802 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2020 BY CPA GLOBAL Effective date: 20190801 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2021 BY CPA GLOBAL Effective date: 20200730 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2022 BY CPA GLOBAL Effective date: 20210805 |
|
| LAPS | Patent lapsed |